News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ReVance Therapeutics, Inc. Announces Initiation Of Phase Ib Clinical Trial Of Topically Applied Botulinum Toxin Type A Gel For The Treatment Of Facial Aesthetics


11/9/2006 11:37:49 AM

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Revance), today announced it has initiated a Phase Ib clinical trial of the Company's lead drug candidate, a topically delivered botulinum toxin type A gel for the treatment of facial lines and wrinkles. The randomized, placebo-controlled, clinical trial is designed to evaluate clinical response rates in patients with moderate to severe lateral canthal lines ("crow's feet").

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES